Incorporated in the Republic of Singapore
Company Registration No. 200409104W

MEDIA RELEASE — FOR IMMEDIATE RELEASE 27 August 2026

USP GROUP'S SII FORMS REGIONAL JOINT VENTURE WITH KIMERA HEALTH TO TAKE CLEAN AIR, CALIBRATION AND VALIDATION INTO SOUTHEAST ASIA'S HOSPITALS AND LABORATORIES

Agreement signed at CPHI Korea 2026 in Seoul opens regulated healthcare channels across Singapore, Malaysia and Indonesia. The parties have separately signed a non-binding letter of intent under which SII may acquire up to 51% of the Kimera Health group.

SEOUL / SINGAPORE, 27 August 2026 — USP Group Limited ("USP" or the "Company", and together with its subsidiaries, the "Group") announced on 26 August 2026 that its indirect wholly-owned subsidiary Scientific & Industrial Instrumentation Pte Ltd ("SII") has entered into a joint venture and commercial collaboration agreement with Chimera Flux (S) Pte. Ltd., Kimera Malaysia Sdn. Bhd. and PT Kimera Flux Indonesia — the three companies that trade under the Kimera Health brand.

The agreement was signed at CPHI Korea 2026 at COEX, Seoul, the same day, and covers Singapore, Malaysia and Indonesia. It brings together two complementary portfolios: SII's laboratory and precision instrumentation, calibration, validation and environmental monitoring solutions, and Kimera Health's surgical robotics, orthopaedic and spinal implants, surgical power tools and bio-materials. SII will also offer the Group's IQAir clean air solutions, for which the Group is the appointed nationwide distributor in Singapore and Indonesia.

What the joint venture does

The parties will cross-sell and up-sell each other's products and services to a combined customer base of hospitals, surgical centres, specialist clinics, diagnostic and clinical laboratories, pharmaceutical and medical device manufacturers, and public health institutions across the three markets.

Kimera Health will also make its medical device licences and regulatory registrations available to support the registration and listing of SII products with the relevant health authorities — the Health Sciences Authority in Singapore, the Medical Device Authority in Malaysia and the Ministry of Health in Indonesia. This is intended to open a route for SII's calibration, validation and environmental monitoring services across all three markets, and for the Group's IQAir clinical-grade clean air systems in Singapore and Indonesia, into channels that require medical device registration to sell into. Kimera Health holds importer and wholesaler licences from Singapore's Health Sciences Authority, an establishment licence from Malaysia's Medical Device Authority, and a distributor licence and Good Distribution Practice certification in Indonesia.

A Joint Steering Committee, with two representatives from each side, will meet quarterly to set the annual business plan, pricing framework and registration priorities. The initial term is three years.

Why it matters

Air quality and environmental control have moved from a facilities concern to a clinical one. Operating theatres, sterile services departments, isolation and immunocompromised wards, IVF and cell therapy laboratories, compounding pharmacies and GMP cleanrooms all depend on controlled air and on instruments that are demonstrably calibrated and validated. Those are the same rooms Kimera Health already sells into.

For the Group, the joint venture extends commercial reach across three markets without capital contribution, acquisition consideration or new fixed infrastructure — and adds regulatory access that would otherwise take considerable time and cost to build.

> *"SII has been calibrating and validating instruments for Singapore's laboratories and industry for fifty years, and the Group has built a clean air business around IQAir. What we have not had is a direct route into the regulated healthcare channel, where both are genuinely needed. Kimera Health has that route, and licences and relationships we would take years to replicate. This partnership is straightforward: their access, our engineering, the same customers."*

Mr Melvin Tan Wei Yang, Executive Director and Chief Executive Officer of USP Group Limited, and Chief Executive Officer of SII

> *"We sell into operating theatres and surgical centres every day, and our customers keep asking us about air quality, environmental monitoring and instrument validation. SII already does that work to a standard we can put our name to. Bringing their portfolio through our regulatory and distribution platform lets us answer more of what our customers need, in three markets at once."*

Mr Henry Kwee, Managing Director, Kimera Health

Letter of intent

Separately, SII and USP have signed a non-binding letter of intent with the shareholders of the Kimera Health companies, recording their intention to negotiate in good faith towards an acquisition by SII of up to 51% of the issued share capital of one or more of those companies. SII would be both the joint venture counterparty and the acquirer, so the commercial relationship and the equity interest sit in the same company. Any such acquisition would be subject to due diligence, agreement on valuation, definitive documentation and all necessary approvals, including those under the Listing Manual of the Singapore Exchange Securities Trading Limited ("SGX-ST"). Other than a limited number of provisions, the letter of intent is not legally binding, and there is no assurance that any acquisition will proceed.

About USP Group Limited

USP Group Limited (SGX:BRS) is a company incorporated in Singapore and listed on the Mainboard of the SGX-ST. Through its subsidiaries — including Supratechnic, Scientific & Industrial Instrumentation and the SupraYi e-commerce platform — the Group provides clean air, healthcare, instrumentation and marine solutions across Singapore, Malaysia and Indonesia. The Company was discharged from judicial management with effect from 18 July 2026. Trading in its shares has been suspended since 23 February 2024, and the Company is preparing a resumption of trading proposal for submission to the SGX-ST. More information is available at uspgroup.com.sg.

About Scientific & Industrial Instrumentation Pte Ltd

Scientific & Industrial Instrumentation Pte Ltd (UEN 197501192W), established in 1975, is an indirect wholly-owned subsidiary of USP Group Limited and one of the Group's principal operating businesses. It distributes laboratory, scientific and precision instrumentation and gas detection and safety systems, and provides calibration, validation and environmental monitoring services. Through the joint venture it will also offer the Group's IQAir clean air solutions, for which the Group is the appointed nationwide distributor in Singapore and Indonesia. Its registered principal activity is the wholesale of medical, professional, scientific and precision equipment. More information is available at sii.asia.

About Kimera Health

Established in 2021, Kimera Health is a medical technology distribution group operating in Singapore, Malaysia and Indonesia through Chimera Flux (S) Pte. Ltd. (UEN 202115579M), Kimera Malaysia Sdn. Bhd. (Registration No. 202101025904 (1426204-T)) and PT Kimera Flux Indonesia (NIB 1101220038285). Its portfolio includes surgical robotic systems, hip and knee replacement products, spinal and orthopaedic implants, surgical power tools and bio-materials, supplied to hospitals, surgical centres and specialist practices across the three markets. More information is available at kimerahealth.com.

Photograph

Caption: Front row, from left: Mr Henry Kwee, Managing Director of Kimera Health (second from left), and Mr Melvin Tan Wei Yang, Executive Director and Chief Executive Officer of USP Group Limited and Chief Executive Officer of Scientific & Industrial Instrumentation Pte Ltd (fifth from left), with delegates in Seoul during CPHI Korea 2026.

Short caption (social / wire): Henry Kwee, Managing Director of Kimera Health, and Melvin Tan, Executive Director & CEO of USP Group Limited, with delegates at CPHI Korea 2026, Seoul.

Credit: USP Group Limited. High-resolution image available on request.

Media and Investor Contacts

For media and investor enquiries, please contact:

Contact	Role	Email / Telephone
Ms Emily Ting	Finance and Human Resources Manager, USP Group Limited	emily@uspgroup.com.sg +65 6862 2100
Mr Leow Yong Kin (Louis)	Chief Financial Officer and Joint Company Secretary, USP Group Limited	louis@uspgroup.com.sg +65 6862 2100
Mr Henry Kwee	Managing Director, Kimera Health	henry@chimeraflex.com +65 9238 0403

Important Notice

This press release should be read in conjunction with the Company's announcement released on SGXNET on 26 August 2026, which prevails in the event of any inconsistency. Statements in this release that are not statements of historical fact are forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors, are based on assumptions current as at the date of this release, and are not guarantees of future performance. Actual outcomes may differ materially. The expected benefits of the joint venture may not be realised in whole or in part; the proposed acquisition described above remains subject to due diligence, valuation, definitive documentation and all necessary approvals, and may not proceed. Nothing in this release constitutes an indication as to whether, when or on what terms trading in the Company's shares may resume. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company and, if in any doubt, to consult their professional advisers.